Trial Profile
A randomized trial to compare the changes in the systemic VEGF protein levels following intravitreal injections of Aflibercept or Ranibizumab in patients with wet age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 25 Sep 2015 New trial record